1. Introduction {#s0005}
===============

Mammalian lipase family plays a vital role in sustaining normal plasma levels, accountable for involving numerous enzymes such as hepatic, endothelial, pancreatic, gastric and lipoprotein lipases (LPL) ([@b0005]). The LPL deficiency is infrequently inherited disease characterized by chylomicronemia, severe hypertriglyceridemia, and risk of recurrent pancreatitis ([@b0010]). One of the key enzymes in LPL will regulate triglyceride (TG) metabolism along with high density lipoprotein-cholesterol (HDL-C) ([@b0015]). LPL promotes modifies the lipids between very low-density lipoprotein to HDLC ([@b0020]). Previous studies have discovered dyslipidemia as a risk factor in Coronary artery disease (CAD), which have been explored the genetic role of polymorphisms in the LPL gene ([@b0025]). LPL plays the role of non-catalytic bridging as one of the ligands in lipoprotein cell surface interaction in uptake of lipoproteins ([@b0030]). Enzymatic glycoprotein is known to be as LPL, which involves 448 amino-acids with a very well significant role in hydrolyzing triglycerides (TG) ([@b0035]). Genetic modification in the LPL gene in which LPL low levels are associated with one of the increased CAD risk factors ([@b0040]). The critical elevation in TG values were associated with molecular variants in the LPL gene which lower the LPL activities and due to this LPL is linked with specific metabolic syndrome as type 2 diabetes mellitus (T2DM), obesity and non-alcoholic fatty liver disease ([@b0045], [@b0050]). LPL plays an essential role in lipoprotein metabolism as well as in chylomicrons. As per the results, free fatty acids and monoglycerides are formed for usage in energy production and storage. The LPL gene consists of 10 exons and 11 introns, which spans about 35 kilobases in size; the accurate chromosomal location is at 8p22 and till now, more than 100 mutations have been identified. ([@b0055]).

Cardiac diseases are the combined combination of CAD and hypertension for major causes of death ([@b0060]). The CAD has been confirmed through the epidemiological studies as multigene cum multifactorial regulated human disease ([@b0065]). The estimated mortality rate will be about 23 million by 2030 ([@b0070]). Nine million deaths have been recorded in all ages of subjects with CAD and known to be the one of the cause of mortality global-wide ([@b0075]). The major cause of CAD is atherosclerosis which further precede for coronary heart disease (CHD). The appearance of atherosclerosis will be symptomatic phase and can confirmed as coronary artery calcification in the CAD ([@b0080]). CAD is one type of cardiovascular disease that is affected due to a low amount of oxygen and the appearance of blood in the heart ([@b0085]). The combination of genetic and environmental factors plays a significant role in the progression and pathogenesis of CAD ([@b0090]). Physical activity, diet and smoking are the major flaws connected with environmental causes ([@b0095], [@b0100]). T2DM is one of the risk factor CAD, stroke and CHD events atleast through two-to-three folds and simultaneously, T2DM have the maximum chances of developing CAD which is highly tends to be a complex disease ([@b0105], [@b0110]). The etiology of CAD is remains to be obscure and heritability rate was documented to be between 40 and 60% as per family and twin studies ([@b0115]).

Genome-wide association studies have identified numerous loci for the CAD and one of the main susceptibility loci is placed at chromosome 15q26.1 which exists the single nucleotide polymorphism in the form of rs17514846 ([@b0120]). Several case-control and *meta*-analysis studies have shown the relation between LPL gene and CAD ([@b0040], [@b0125], [@b0130], [@b0135], [@b0140], [@b0145], [@b0150]). The accurate genetic and molecular or any other mechanism which affects the LPL and human disease is poorly understood and LDL was interrelated towards certain heterogenous disorders which involve limited cardiovascular disorders ([@b0155]). The rs320 polymorphism has been studied globally in CAD, stroke, dyslipidemia ([@b0125], [@b0160], [@b0165], [@b0170], [@b0175], [@b0180]) and this polymorphism is located between the intron 6--8 and important role of rs320 polymorphism could elevate the atherosclerosis risk through influencing plasma lipid levels ([@b0185]). LPL variants, Ser447stop (S447X) are connected to a decline in LPL activity while Asn291Ser (N291S) and Asp9Asn (D9N) with an elevation in LPL activity. Thus, these variants could affect lipid profile levels and lead to CAD eventually ([@b0190]). A Prior study results from Saudi Arabia have showed that significant linkage occur between HindIII polymorphism (rs320), Ser447Ter Pvull polymorphisms and changes in plasma lipids levels in CAD patients ([@b0195]). Although the results from previous studies have highlighted the role of polymorphisms at LPL gene in causing CAD, not all of the polymorphisms have showed significant correlations to CAD. Here, we study the effects of the genetic variant, HindIII at the position 481 in intron 8 (T → G), on lipid profile levels and its association to CAD occurrence.

2. Materials and methods {#s0010}
========================

2.1. Study subjects {#s0015}
-------------------

In this case-control study, we have selected 520 subjects confirmed as 315 cases and 205 controls recruited during the time-phrase of September-2013 to May-2015 from King Abdullah Medical city (KAMC) and Al-Noor specialist hospitals appears at the western region of Saudi Arabia. The inclusion criteria of the CAD cases were based on complete investigation achieved in the hospital premises. The age range of the involved cases were in between 30 and 85 years of age with 50% higher than the stenosis of coronary arteries. T2DM patients were confirmed through American Diabetes Association criteria ([@b0200]), while dyslipidemia cases were confirmed by prior studies ([@b0205]). Body Mass Index was calculated as per the described study ([@b0210]) and hypertension was determined as systolic blood pressure as ≥ 140 mmHg and diastolic blood pressure as ≥ 90 mmHg ([@b0215], [@b0220]). The age and gender controls were opted without any histories of peripheral vascular disease, CAD and stroke. Patients with malignancies and other auto-immune diseases were also excluded from our study. Ethical grant was obtained from Umm Al-Qura University-43430838 in 05/05/1434H and KAMC-13--043. All the involved participants have signed the informed consent form. All chosen methods were executed in accordance with the relevant guidelines and regulations of Umm Al-Qura University and King Abdullah Medical City. Documented and enlightened consent was acquired from every study participant. Data on diverse parameters such as age, sex, smoking, diet, height, and weight were enrolled.

2.2. Biochemical assays {#s0020}
-----------------------

From each patient, 10 mL of blood sample was collected and divided into serum and EDTA vacutainers ([@b0225]). Five mL of the serum sample was used for fasting glucose, lipid profiles and cardiac markers; whereas the remaining 5 mL of the peripheral blood was collected to extract the DNA. Biochemical analysis was carried out with the described studies ([@b0090], [@b0230]).

2.3. Molecular assays {#s0025}
---------------------

GeneJet-DNA extraction purification kit was used to isolate the genomic DNA through the described protocol and stored in the −20 °C for further usage. NanoDrop spectrophotometer was used to measure the quality and quantity of the genomic DNA ([@b0235]). Genotyping was performed using polymerase chain reaction followed with restriction fragment length polymorphism analysis ([@b0240]). The primers for intron-8 region of LPL gene was adopted from the prior studies ([@b0125], [@b0245], [@b0250]). Amplification was performed using GoTaq colorless master mix (Promega Co. Ltd) in a thermal cycler ([@b0050]). Primers yielded 770 bp as the PCR fragment size. Next, undigested PCR products were digested using 10U of *Hind*III restriction enzyme (New England BioLabs Ltd) was added to make the final volume digested products for 25 µL and incubated at room-temperature for 60 min. PCR products further were digested with 3% ethidium bromide stained in the agarose gel ([@b0255]). GG homozygotes were found to be 770 bp; TT homozygotes were divided into 600/170 bp and heterozygotes were found to be 770/600/170 bp respectively ([Fig. 1](#f0005){ref-type="fig"}).

2.4. Data analysis {#s0030}
------------------

Statistical data was analysed using SPSS (version 23.0) and Openepi softwares as described ([@b0260]). Clinical data was expressed as mean ± standard deviation. Genotype and allele frequencies were calculated as per the presence of difference alleles observed and complete number of alleles inspected using odds ratio's (OR's) and 95% confidence intervals (CI's). Fischer's exact *t*-test were also attained. Non-parametric Krushkal Wallis test was used to compare the mean ranks of skewed quantitative variables in relation to the three products of) *LPL* gene G \> T locus. (TT, GT & GG). Significance was set-up as p \< 0.05 ([@b0265]).

3. Results {#s0035}
==========

The study recruited 315 coronary artery diseases patients with more than 50% stenosis confirmed on coronary angiography and 205 aged-matched controls. The characteristics of the participants ([Table 1](#t0005){ref-type="table"}) revealed fairly equaled distribution by age as the patients had mean age and SD of \[59.7 (10.87)\] versus that of controls of \[58.4 (9.28)\] with a p value of 0.157. In addition, patients largely demonstrated more characteristics than controls in the following parameters: body mass index 29.26 (4.11) vs. 26.26 (6.49) \[p 0.000\], smoking status 150 (47.6%) vs. 58 (28.3%) \[p 0.000\], exercise habits 72 (22.9%) vs. 67 (32.7%) \[p 0.009\], diabetes mellitus 187 (59.4%) vs. 35 (17.1%) \[p 0.000\], and blood glucose levels 140.64 mg/dl vs. 83.56 mg/dl \[p 0.000\].Table 1Clinical characteristics features between CAD cases and controls.VariablesCAD cases (n = 315)Controls (n = 205)PvaluesAge (Mean ± SD)59.7 (10.87)58.4 (9.28)0.157BMI (Mean ± SD)29.26 (4.11)26.26 (6.49)0.000Gender (Male%)206 (65.4%)119 (58%)0.055Smoking (%)150 (47.6%)58 (28.3%)0.000Exercise (%)72 (22.9%)67 (32.7%)0.009Diabetes (%)187 (59.4%)35 (17.1%)0.000Fasting glucose (mg/dl)140.6483.560.000Hypertension (%)221 (70.2%)41 (20%)0.000SBP (mmHg)146.47122.030.000DBP (mmHg)91.8474.250.000Event Stroke (%)72 (22.9%)7 (3.4%)0.000Total Cholesterol (mg/dl)154.17 (23.6)140.88 (18.09)0.000HDL-c (mg/dl)39.95 (8.05)41.14 (8.65)0.111LDL-c (mg/dl)115.89 (38.28)88.6 (30.18)0.000Triglycerides (mg/dl)145.97 (60.27)120.12 (22.71)0.000

The presence of hypertension and events of stroke in patients as compared to controls were statistically: hypertension 221 (70.2%) vs. 41 (20%) \[p 0.000\], systolic pressure 146.47 vs. 122.03 mmHg (p 0.000), diastolic pressure 91.84 vs. 74.25 mmHg (p 0.000), and events of stroke 72 (22.9%) vs. 7 (3.4%) \[p 0.000\]. Furthermore, lipid profile revealed significant difference in measured total cholesterol, LDL, triglycerides and curiously the seemingly protective HDL showed no dissimilarity between patients and controls.

The distribution of genotypes ([Table 2](#t0010){ref-type="table"}) were in decreasing order TT, 148 (47%), GT 135 (42.9%) and GG 32 (10.2%) in the cases of the study while the pattern in controls were GT 91 (44.4%), TT 86 (42%) and GG 28 (13.7%). [Fig. 1](#f0005){ref-type="fig"} depicted the position of G and T alleles on intron 8 of the LPL gene. Cases were likely than controls to have all the genotypes in this study. Among the two of the genotypes of HindIII, none were statistically significant as the odd ratios between the cases and controls were as follows: TT \[OR = 1.506, 95% CI (0.849--2.670), p 0.182\] and GT \[OR = 1.298, 95% CI (0.732--2.301), p 0.227\]. Alleles distribution among cases and controls were more with T than G, however they were not statistically significant as the OR = 0.826, 95%CI (0.635--1.074), p0.087.Table 2Genotype and allele frequencies between CAD cases and control subjects.**Case (3 1 5)Control (2 0 5)OR95% CI*P*Genotypes**No.%No.%GG3210.22813.71GT13542.99144.41.298(0.732--2.301)0.227TT1484786421.506(0.849--2.670)0.182**Alleles**G19931.5914735.850.826(0.635--1.074)0.087T43168.4126364.15Fig. 1Digested PCR products for Hind*III* polymorphism.

Comparison of risk parameters across the genotypes ([Table 3](#t0015){ref-type="table"}) demonstrated insignificance except for BMI which showed differential change towards the GG genotype (p = 0.032). Analysis of the effects of HDL-c across all patients ([Table 4](#t0020){ref-type="table"}) revealed statistically significant difference for males (p = 0.000), diabetics (p = 0.000) and triglycerides \< 150 mg/dl (p = 0.033). While no differences were noted for obesity and smoking. Regression analysis of associated factors in [Table 5](#t0025){ref-type="table"} demonstrated significance of G Allele and other parameters except for age (p = 0.513), smoking (p = 0.176) and exercise (p = 0.329).Table 3Risk factors distribution across genotypes.No. (%)TTGTGG*P*Age \[mean(SD)\]59.42 (11.28)59.56 (10.55)61.59 (10.40)0.581BMI (Kg/m^2^) \[mean(SD)\]28.83 (3.9)29.33 (4.11)30.92 (4.74)**0.032**Gender (male %)105 (33.33%)85 (26.98%)16 (5.08%)0.057Smoking76 (24.13%)64 (20.32%)10 (3.17%)0.118Exercise (%)35 (11.11%)30 (9.52%)7 (2.22%)0.951Hypertension (%)99 (31.43%)98 (31.11%)24 (7.62%)0.474Systolic BP (mmHg)146.47 (12.66)147.04 (12.12)144.01 (12.07)0.462Diastolic BP (mmHg)92.03 (10.17)90.58 (9.46)92.70 (9.09)0.349Diabetes (%)88 (27.94%)77 (24.44%)22 (6.98%)0.479Blood glucose (mg/dl)141.46 (21.36)140.32 (20.36)138.18 (19.84)0.701Stroke (%)41 (13.02%)22 (6.98%)9 (2.86%)0.065TC (mg/dL)155.37 (22.48)152.38 (24.79)156.17 (23.70)0.500LDLc (mg/dL)117.35 (43.35)113.80 (24.79)117.97 (45.72)0.701HDLc (mg/dL)39.78 (8.55)39.97 (7.50)40.65 (8.13)0.859TG (mg/dL)143.31 (59.34)146.34 (59.91)156.75 (66.50)0.519Table 4Effects of environmental factors on plasma HDL-c levels.FactorNHDL-cMean difference*-tP*GenderMale20637.43 ± 7.2− 7.275− 8.442**0.000**Female10944.71 ± 7.4ObesityBMI \< 30 kg/m^2^18540.06 ± 8.1−0.268−0.2910.772BMI ≥ 30 kg/m^2^13039.79 ± 8SmokingYes15039.51 ± 7.70.8440.9330.353No16540.35 ± 8.3DiabetesYes18737.83 ± 7.6−5.23−5.968**0.000**No12843.06 ± 7.7TGTG \< 150 mg/dl16140.89 ± 7.81.932.14**0.033**TG ≥ 150 mg/dl15438.97 ± 8.2Table 5Regression analysis with associated risk factors.VariablesB*BetatP*LPL G Allele− 0.001− 0.008− 0.459**0.046**Age0.0010.0120.6540.513BMI0.0040.0492.674**0.008**Smoking0.310.0311.3550.176Exercise− 0.019− 0.017− 0.9760.329Hypertension0.0560.0582.686**0.007**Systolic BP0.0080.25611.114**0.000**Diastolic BP0.0070.1918.972**0.000**DM0.0440.0442.188**0.029**Fasting Glucose conc0.0070.47218.896**0.000**TG0.0010.0603.334**0.001**TC0.0010.0603.341**0.001**LDL-c0.0010.0643.462**0.001**HDL-c− 0.001− 0.012− 0.687**0.049**

4. Discussion {#s0040}
=============

The aim of the present study was to investigate the genetic association of rs320 polymorphism in LPL gene in the diagnosed CAD cases in Saudi population. The results of this study confirm the negative association either with allele or genotype frequencies (p \> 0.05) between the CAD cases and control subjects.

LPL is a key-enzyme for the lipid metabolism and it can hydrolyze the TG of chylomicrons and VLDL to provide free fatty-acids for oxidation and exploitation in heart and other tissues for storing in adipose tissues. LPL is a pathophysiological procedure for chylomicronemia, diabetes, obesity and atherosclerosis. *LPL* gene is cDNA translated into 475 amino-acid proteins which involves signal peptide of 27 amino-acids. RFLP in *LPL* gene has confirmed BamHI, BstNI, *Hind*III, PvuII and Ser447X sites. *Hind*III is one of the polymorphisms amongst in which plasma lipids were associated and lowers the plasma LPL activities; further subordinates with high TG and low HDL-c levels which may contribute in the CAD patients. The HindIII variant exists 495 bp from the intron-8 towards the splice site and effect the RNA splicing. The H-allele in this variant may enhance the enzyme activity ([@b0150]). However, other studies have confirmed various discrepancies regarding the TG level, incidence of myocardial and rate of acute ischemic strokes in different geographical locations and ethnicities.

Our study located in western part of Saudi Arabia revealed elevated total cholesterol, low density cholesterol and triglycerides among patients with coronary artery disease as compared. This is conformity of the results in central province of Saudi Arabia where CAD patients demonstrated drastically greater TG, TC and LDL-c levels than controls in patients with Hind*III* among other genotypes. Furthermore, similar to our study, the genotype was linked with significantly reduced HDL-c levels. Both the studies have recognized the connection between Hind*III* variant and high plasma levels in TC, TG and LDL-c with low HDL-c levels ([@b0195]).

Despite the significant differences in lipid profile between cases and controls, the Hind*III* polymorphism did not exert an independent vulnerability to the development of CAD. Our study revealed insignificant odd risk ratios among the haplotypes in both cases and controls. The findings were similar to studies done among Saudi population in central province of the country. Furthermore, the frequencies of Hind*III* in our study (TT, 47.0; GT, 42.9 and GG, 10.2%) were similar in these studies as Daoud et al. ([@b0195]) recorded (TT, 45.1; TG, 35.8 and GG, 19%) while Abu Amero et al. ([@b0270]) reported slightly similar (TT, 53.7; TG, 39.2 and GG, 7.1%). These studies proved the fact that *LPL*-Hind*III* polymorphism could not be used as an independent genetic risk factor for CAD in Saudi Arab populations. Both the genetic and environmental factors like HTN, diabetes, obesity and smoking are important risk-factors for the development of CAD. In North Africa, the polymorphisms assessed by restriction assay in 100 each of diabetic and non-diabetic Egyptian MI patients and 100 healthy controls demonstrated that individuals with the H2H2 genotype or S2 allele three times more likely to suffer from MI than those carrying the H1H1 or S1S1 ([@b0275]). Despite cultural linkage with the Saudi population, our study and others did not show significant association between myocardial infarction in patients with diabetes across all haplotypes of Hind*III* polymorphism ([@b0130], [@b0270]).

In the Mediterranean area, a Spanish study which analysed various genetic variants including Hind*III* in a large, well-characterized population, illustrated their association with TG levels. The results demonstrated a liberated effect of the polymorphisms studied, notably TG-lowering Hind*III* case ([@b0280]). The protective LPL variants Hind*III* were also shown in other populations from southern Europe. In contrast, our study reported raised levels of triglycerides. The differences may well be due to the effects of geographical and ethnic dissimilarities between populations of the studies. In conformity with our finding of dyslipidemia, an Iranian study which evaluated 725 children and adolescents demonstrated the relationship of LPL Hind*III* \[rs320\] and abnormal lipid levels ([@b0285]).

In an appraisal of the associations between seven LPL polymorphisms, lipid fractions and CHD risks in a population-based cohort, case-control, and cross-sectional studies, Sagoo et al ([@b0290]) analysed populations comprising 22,734 CHD cases and 50,177 controls. The study reviewed the relationship between various polymorphisms including Hind*III* to TG, HDL-c, myocardial infarction, or coronary stenosis. It was demonstrated that carriers of the less common allele of Hind*III* depicted modestly advantageous profiles. Furthermore, subset assessment of 8186 participants revealed that carriers of the less common allele of the Hind*III* polymorphism higher HDL-c levels and lower TG levels than non-carriers. The findings of our study conformed with higher HDL-c but at variance with lower triglyceride levels as the *meta*-analysis was composed of large population of participants and varying geographic settings of white European continental ancestry, East Asian, including Mexican-American and Turkish populations.

The event of acute stroke in our study though a small population of participants was 22.9% in cases and 3.4% in controls with a p Value of 0.000. In Colombia, Velasquez et al ([@b0180]), did not record any association between LPL gene polymorphisms including HindIII and acute ischemic stroke in the population studied ([@b0295]). In addition, the allele and genotypic frequencies of the studied polymorphisms were similar in cases and controls. However, in a *meta*-analysis of studies in five Chinese and Japanese population, it was revealed that *LPL*-*Hind*III was protective factor against stroke risk. Further stratification showed the protective role played simultaneously for both hemorrhagic and ischemic subtypes. It was postulated that rs320 produces a significant impact on precursor RNA which may be a source of the protective effect of the polymorphism in stroke propensity ([@b0300]). Lipid profile in Colombian study were not significantly different between cases and controls despite the lack of association between Hind*III* and the stroke risk. However, the controls had statistically significant high levels of HDL-c than the cases ([@b0295]).

The limitations of our study are; (i) we couldn't provide the validation results (ii) participants were recruited from couple of hospitals placed in the western region and (iii) we miss the plasma levels for LPL through Elisa. A multi-centre study would have in addition, as in case-control studies, selection bias would have been difficult to be avoided. The strength of our study is we have opted good sample size with age and gender matched controls. Our study couldn't conclude the positive association with Hind*III* polymorphism in CAD patient and controls. However, other global studies have confirmed as biomarker with rs320 or Hind*III* polymorphism. At other angle, our study showed Hind*III* polymorphism in *LPL* gene was associated with raised TG levels and stroke. However, no associations were recorded with all haplotypes on the risk of myocardial infarction, lipid profile and other established diseases associated with myocardial infarction. Furthermore, the statistical power of the study might be affected as cost was a mitigating factor in ensuring a ratio of 1:3 for cases and controls.
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